Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies has started a single-blind, randomized and placebo-controlled Phase 1 trial to evaluate AZD282 as a treatment for obesity.
Subscribe to our email newsletter
Earlier, Palatin signed a research and licensing deal with AstraZeneca to develop, discover and commercialize compounds targeting melanocortin receptors to treat obesity, diabetes and related metabolic syndrome.
The company expects to recruit around 90 healthy male volunteers in the trial.
AstraZeneca will be responsible to pay milestones to Palatin upon achieving development and regulatory milestones and further paymets on reaching sales target, in addition to royalties on sales of approved products.
The tie up allows AstraZeneca to take forward the commercialization and product discovery and bear the development costs.